Dextroamphetamine Patent Expiration
Dextroamphetamine is Used for treating Attention Deficit Hyperactivity Disorder (ADHD) with a transdermal amphetamine composition. It was first introduced by Noven Pharmaceuticals Inc
Dextroamphetamine Patents
Given below is the list of patents protecting Dextroamphetamine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xelstrym | US11559501 | Transdermal amphetamine compositions with low levels of carbamate | Jan 06, 2042 | Noven Pharms Inc |
| Xelstrym | US9456993 | Compositions and methods for transdermal delivery of amphetamine | Oct 24, 2033 | Noven Pharms Inc |
| Xelstrym | US9474722 | Compositions and methods for transdermal delivery of amphetamine | Oct 24, 2033 | Noven Pharms Inc |
| Xelstrym | US8591941 | Transdermal drug delivery device including an occlusive backing | Oct 07, 2025 | Noven Pharms Inc |
| Xelstrym | US8632802 | Device for transdermal administration of drugs including acrylic polymers | Oct 07, 2025 | Noven Pharms Inc |
| Xelstrym | US9034370 | Device for transdermal administration of drugs including acrylic polymers | Oct 07, 2025 | Noven Pharms Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dextroamphetamine's patents.
Latest Legal Activities on Dextroamphetamine's Patents
Given below is the list recent legal activities going on the following patents of Dextroamphetamine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 24 Jan, 2023 | US11559501 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Jan, 2023 | US11559501 |
| Email Notification Critical | 05 Jan, 2023 | US11559501 |
| Issue Notification Mailed Critical | 04 Jan, 2023 | US11559501 |
| Dispatch to FDC | 23 Dec, 2022 | US11559501 |
| Application Is Considered Ready for Issue Critical | 23 Dec, 2022 | US11559501 |
| Response to Reasons for Allowance | 16 Dec, 2022 | US11559501 |
| Issue Fee Payment Verified Critical | 16 Dec, 2022 | US11559501 |
| Issue Fee Payment Received Critical | 16 Dec, 2022 | US11559501 |
| Electronic Review Critical | 22 Nov, 2022 | US11559501 |
Dextroamphetamine's Family Patents
